MFMerve Ekinci Fidan

Merve Ekinci Fidan

*This is an algorithmically generated author record based on publicly available information.

Merve Ekinci Fidan has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort

    by Mehmet Cem Fidan, Ebru Çiçek, Hamza Abbasov, Murad Guliyev, Emir Çerme, Kübra Akkaya, Bekir Doğan, Nargiz Majidova, Burak Paçacı, Ezgi Türkoğlu, et al.

    Background and Objectives: Transfusion-related immunomodulation (TRIM) is a recognized immunosuppressive phenomenon whose interaction with immune checkpoint blockade remains poorly defined. We evaluated the impact of erythrocyte suspension transfusion on survival and immune-related toxicity in patients with metastatic non-small cell lung cancer (NSCLC) treated with nivolumab. Materials and Methods: This retrospective, multicenter study included 253 patients with metastatic NSCLC treated with nivolumab across five centers between April 2018 and March 2025. Patients who received a transfusion within three months before or during nivolumab therapy were compared with non-transfused patients. Survival was assessed using Kaplan–Meier and Cox regression analyses. Results: Forty-two patients (16.6%) received transfusion. Transfused patients had significantly shorter progression-free survival (PFS) (median 3.6 vs. 9.3 months; HR = 2.28, 95% CI 1.47–3.56, p < 0.001) and overall survival (OS) (median 5.8 vs. 16.3 months; HR = 2.76, 95% CI 1.86–4.11, p < 0.001). In multivariable analysis, transfusion was an independent predictor of both shorter PFS (HR = 2.288, 95% CI 1.470–3.561, p < 0.001) and shorter OS (HR = 2.351, 95% CI 1.565–3.533, p < 0.001), independent of transfusion volume. No statistically significant association was detected between transfusion status and the incidence of nivolumab-related toxicity (p = 0.585), although this analysis was likely underpowered, whereas nivolumab-related toxicity was an independent favorable prognostic factor. Conclusions: Erythrocyte transfusion independently predicted poorer survival but not immune-related toxicity in nivolumab-treated metastatic NSCLC, supporting more judicious transfusion practices during immunotherapy.

  • Open Access

    Prognostic factors and survival outcomes in older adults with extensive-stage small cell lung cancer: A multicenter retrospective cohort study

    by Sermin Dinc Sonusen, Zehra Sucuoglu Isleyen, Naime Afsar Satis, Mesut Yilmaz, Bekir Dogan, Senar Gunenc, Tanju Berber, Berna Akkus Yildirim, Yaren Ceran Bas, Merve Ekinci Fidan, et al.

    Extensive-stage small cell lung cancer (ES-SCLC) in older adults is associated with poor outcomes, and optimal management in this population remains challenging. This study aimed to identify clinical and treatment-related factors associated with survival in patients aged ≥70 years with ES-SCLC. A retrospective multicenter cohort study included 135 older adults (aged ≥70 years) diagnosed with ES-SCLC across 3 tertiary centers. All patients received at least 1 cycle of platinum–etoposide–based chemotherapy. Demographic, clinical, and treatment variables – including metastatic sites, number of chemotherapy cycles, thoracic radiotherapy (TRT), prophylactic cranial irradiation, and palliative radiotherapy to extracranial metastases – were collected. Survival outcomes were estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic factors for progression-free survival and overall survival (OS) were evaluated using Cox proportional hazards regression models. The median age was 73.2 years; 88.1% of patients were male. The objective response rate was 69.9%. Median progression-free survival and OS were 7.1 and 8.3 months, respectively (95% CI: 6.09–8.17 and 7.67–8.93). In multivariate analysis, Eastern Cooperative Oncology Group performance status ≥2 ( P <.001), liver metastases ( P = .006), fewer than 4 chemotherapy cycles ( P <.001), absence of prophylactic cranial irradiation ( P = .028), and lack of palliative radiotherapy to extracranial metastases ( P <.001) were independently associated with shorter OS. TRT did not retain statistical significance in multivariate analysis. Only 34.1% of patients received second-line therapy. The 1-year and 2-year OS rates were 33% and 12%, respectively. Fit older adults (Eastern Cooperative Oncology Group performance status 0–1) may derive meaningful survival benefit from multimodal treatment strategies. Treatment decisions should be individualized based on functional status rather than chronological age alone. Prospective studies incorporating comprehensive geriatric assessment are warranted.